Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years
International Urology and Nephrology · 2025
DOI: 10.1007/s11255-025-04413-5 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Haobo Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Deoxycytidine, Neoplasm Recurrence, Local, Anthracyclines. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To compare intravesical instillation of gemcitabine and anthracyclines in the treatment of primary non-muscle-invasive bladder cancer (NMIBC), and to evaluate the effect of changing intravesical chemotherapy drugs on the the second recurrence of NMIBC. METHOD: Patients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) for the first time in our center from January 2014 to December 2023 were enrolled. Kaplan-Meier method was used to analyze the recurrence-free survival (RFS) and progression-free survival (PFS), and COX regression was used to analyze the risk factors for recurrence. RESULT: 464 patients were included in the study (212 in the gemcitabine group and 252 in the anthracyclines group). Anthracyclines-treated patients had superior RFS compared to gemcitabine-treated patients (p = 0.006), but PFS did not differ significantly between the two groups (p = 0.654). After the first recurrence of NMIBC, patients who changed intravesical chemotherapy drugs had better RFS than those who kept the original chemotherapy drugs (p = 0.037). In terms of safety, the incidence of adverse events of pirarubicin was significantly higher than that of gemcitabine and epirubicin (55.2% vs 26.4% vs 36.2%, p < 0.001). CONCLUSION: Anthracyclines are more effective than gemcitabine in preventing recurrence of primary NMIBC but with more adverse events. After the first recurrence of NMIBC, changing the drugs of intravesical chemotherapy can reduce the second recurrence of NMIBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
- School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.
- Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. chenyicheng@zju.edu.cn.
Zitieren
APA
Fan, H., Chen, W., Guo, W., Han, J., Xie, H., Yu, Y., Ding, G., & Chen, Y. (2025). Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04413-5
Vancouver
Fan H, Chen W, Guo W, Han J, Xie H, Yu Y, et al. Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04413-5
BibTeX
@article{Fan2025,
author = {Fan, Haobo and Chen, Weiwu and Guo, Wenhao and Han, Jiayu and Xie, Haoze and Yu, Yanlan and Ding, Guoqing and Chen, Yicheng},
title = {Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years},
journal = {International Urology and Nephrology},
year = {2025},
doi = {10.1007/s11255-025-04413-5}
}
EUVIMED